SCHEMBL9957739

SCHEMBL9957739

[c]1ccc(-c2nc(-c3c4ccccc4cc4ccccc34)cc(-c3c4ccccc4cc4ccccc34)n2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 1/20 0.40
ALOX5 P09917 1/20 0.39
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
ALDH1A1 P00352 4/20 0.36
HPGD P15428 3/20 0.36
MAPT P10636 2/20 0.36
NTSR1 P30989 1/20 0.36
MGAM O43451 1/20 0.36
GAA P10253 1/20 0.36
SI P14410 1/20 0.36
MGAM2 Q2M2H8 1/20 0.36
NQO2 P16083 1/20 0.34
ADORA1 P30542 2/20 0.33
ADORA2A P29274 1/20 0.33
CES1 P23141 1/20 0.33
CYP1B1 Q16678 5/20 0.32
HSD17B10 Q99714 2/20 0.32
HTR2A P28223 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10051203 0.85 ALOX5 (0.47) NISCHALOX5MEN1KMT2AALDH1A1
SCHEMBL971280 0.82 MEN1 (0.55) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL1370743 0.81 ALOX5 (0.50) NISCHALOX5MEN1KMT2AALDH1A1
SCHEMBL10051201 0.79 MEN1 (0.56) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL10051303 0.79 MEN1 (0.56) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL10051198 0.77 CYP1A2 (0.51) ALOX5MEN1KMT2AALDH1A1HPGD
SCHEMBL17932622 0.77 MEN1 (0.46) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL9958264 0.76 MEN1 (0.60) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL972800 0.76 ALDH1A1 (0.49) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL10051199 0.76 MEN1 (0.42) ALOX5MEN1KMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9624193-B2 Cyclic azine derivatives, processes for producing these, and organic electroluminescent element containing these as component TOSOH CORPORATION (JP) 2017-04-18 US disclosed
US-20150329544-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT TOSOH CORPORATION (JP) 2015-11-19 US disclosed
US-9120773-B2 Cyclic azine derivatives, processes for producing these, and organic electroluminescent element containing these as component TOSOH CORPORATION (JP) 2015-09-01 US disclosed
EP-2818462-A1 Cyclic azine derivatives, processes for producing these, and organic electrolumiscent element containing these as component TOSOH CORPORATION (JP) 2014-12-31 EP disclosed
US-20120214993-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT SAGAMI CHEMICAL RESEARCH INSTITUTE, (JP) 2012-08-23 US disclosed
EP-2468731-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT Tosoh Corporation (JP) 2012-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329544-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT CPNE4, EPB41, AZI2 NISCH 653/4885ALOX5 517/4885MEN1 405/4885
US-20120214993-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT CPNE4, EPB41, AZI2 NISCH 653/4885ALOX5 517/4885MEN1 405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.